ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
SiNtx Technologies Inc

SiNtx Technologies Inc (SINT)

9.28
-4.24
(-31.36%)
Closed May 29 4:00PM
8.97
-0.31
(-3.34%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
8.97
Bid
8.80
Ask
8.97
Volume
820,905
7.35 Day's Range 9.7399
0.0206 52 Week Range 9.7399
Market Cap
Previous Close
13.52
Open
9.24
Last Trade
50
@
8.9799
Last Trade Time
Financial Volume
$ 6,888,801
VWAP
8.3917
Average Volume (3m)
69,414,134
Shares Outstanding
4,259,758
Dividend Yield
-
PE Ratio
-4.92
Earnings Per Share (EPS)
-1.94
Revenue
2.63M
Net Profit
-8.29M

About SiNtx Technologies Inc

SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatmen... SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
SiNtx Technologies Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker SINT. The last closing price for SiNtx Technologies was $13.52. Over the last year, SiNtx Technologies shares have traded in a share price range of $ 0.0206 to $ 9.7399.

SiNtx Technologies currently has 4,259,758 shares outstanding. The market capitalization of SiNtx Technologies is $40.77 million. SiNtx Technologies has a price to earnings ratio (PE ratio) of -4.92.

SINT Latest News

SINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE MAY 28, 2024

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) today announced that its Board of Directors has declared a 1-for-200 reverse stock split of the company’s...

SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT

Salt Lake City and Paris., April 29, 2024 (GLOBE NEWSWIRE) -- Advanced technical ceramic company, SINTX Technologies, Inc., ((NASDAQ: SINT: “SINTX” or the “Company”) and Prodways Printers SAS...

SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock

SALT LAKE CITY, UT, April 03, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today...

SINTX Technologies Announces Proposed Public Offering of Common Stock

SALT LAKE CITY, UT, March 29, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today...

SINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stock

SALT LAKE CITY, UT, March 25, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
18.8749243.750.0969.73990.066569534160.08203677CS
48.919817768.52589640.05029.73990.0331158013040.11033571CS
128.83456519.926199260.13559.73990.0206694141340.07798053CS
268.57652179.542566710.39359.73990.0206335862340.08192853CS
527.58545.3237410071.399.73990.0206167162210.08460764CS
156-144.03-94.137254902153205.50.020663363155.36139367CS
260-10.53-5419.55500.0206504558846.75661765CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.42M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.46M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
85M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.68M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.67M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.62M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

SINT Discussion

View Posts
boston745 boston745 7 hours ago
In addition to the possible use of Silicon Nitride for the creation of membranes to filter tumerous cells, Si3N4 can also be used for biosensors to detect cancerous cells:

Design and bulk sensitivity analysis of a silicon nitride photonic biosensor for cancer cell detection
We proposed silicon nitride MZI sensor architecture as integrated biosensor for point-of-care device. This biosensor detects virus and biomolecules fast and is cost-effective. Our simulated analysis determines optimized waveguide geometry that maximizes the bulk sensitivity. MZI utilizes the refractive index of different cancer cells (1.39–1.401) to determine the waveguide bulk sensitivity .
The absorption of cancer cells at three wavelengths 1563?nm, 1573?nm, and 1579?nm offers high detection rate compared with the standard rib waveguide. The silicon nitride-based waveguide biosensor may be fabricated using CMOS E-beam lithography, and its stability will be matched to the simulated results. The proposed biosensor can provide test results in a short time than the conventional biopsy, which takes two days to detect cancer cells.
https://www.hindawi.com/journals/ijo/2022/6085833/

Ultrathin silicon nitride membrane with slit-shaped pores for high-performance separation of circulating tumor cells

The silicon nitride (Si3N4) filtering membrane was fabricated via the standard microfabrication technology, which can be easily scaled up to mass-production. 6 µm was determined as the optimum width of the filtering pores to better separate CTCs in whole blood, which can reach a high capture efficiency of ~96%.
https://pubmed.ncbi.nlm.nih.gov/35997043/


https://i.imgur.com/FhLd8in.jpeg

Sintx has a collaboration to develop product(s) for cancer treatment. What that product or products is has not yet been disclosed. Furthermore, metal implants increase the liklihood of patients getting cancer so replacing metal implants with Si3N4 could reduce risk of developing cancer as well.
A company with cancer treating product potential is current worth less than $10m.

https://d1io3yog0oux5.cloudfront.net/_8f0fdfcc546b780f57d6517861862db9/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️ 1 ❤️ 1
boston745 boston745 13 hours ago
This happens every RS, always drops a good 30-50% There is usually chances to increase back to RS price afterwards during sideways trading before offering especially if funds are going to Naked short the offering like they did every offering last year. There is no selling its just funds working the price and shaking any shares they can. Barely any retail shares bought during the pump before the RS. Like 5000 shares traded retail after factoring in the 200:1 RS.
Retail needs to hold every share and buy as many as they can to reduce this game. Still based on what Xena said in a previous post they have alot of tools at their disposal to work the price. Rigged game.


Update on Sintx stockholders equity is about $10m. Based on Float number disclosed before RS current valuation is $5.9m based on a price around 8.32. Thus shares are discounted below stockholders equity.

Shares Float: 141,846,000 pre RS
Post RS = 709,230

https://stocktwits.com/HaltTradeAlert/message/574273137



========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️0
joev2 joev2 15 hours ago
Sorta like a driver who supposedly hasn't a clue but just an affinity towards mask wearers with guns, who need a ride every so often after visiting a bank. Meanwhile, the driver and his family can't understand why he's on the most wanted list as well? Sorry, management is much more than a tool IF what you say is true.
👍️0
Disquisition Disquisition 15 hours ago
UNIMAGINABLE DUMPING
👍️0
XenaLives XenaLives 15 hours ago
AMLN tripled before that buy out...

👍️0
XenaLives XenaLives 16 hours ago
Nope - it's the big money calling the shots - the management team is just a tool.

Zimmer still has a lot of active lawsuits. They don't want to show their cards and expose the fact that they knew they were poisoning people.
👍️0
XenaLives XenaLives 16 hours ago
This is nuts.. took some nice profits and sold all but one share.

I still have one share but it's worth $9+ now.
👍️0
db101 db101 20 hours ago
A 1:200 split took place…
👍️0
CarlCarlMcB CarlCarlMcB 24 hours ago
Over 19.00 !!!!
👍️0
boston745 boston745 1 day ago
some cretin posts hallucinogenic messages on ST
Ya i dont believe "some cretin" posted the original post that the person on ST screenshot and then posted on ST. I believe its purposeful misinformation. Did they chose Eli Lilly or Lilly Eli because i often mention Amylin & Eli Lilly to compare to Sintx and Zimmer Biomet? That screenshot also came after i posted about Si3N4 being used for Cancer treatment which would be up Eli Lilly's alley. Not sure they'd use those membranes for tumor cell filtration or Solventum would? But that product is just a guess as to what is being developed with a partner for cancer treatment.

The parallels between Sintx and Amylin are uncanny. Both being co-founded by individuals connected to major players in their fields with personnel from those large players being on their respective boards most of their existence. While i thought Mr. Icahn came in and ruined the eventual acquisition of Amylin by Eli Lilly, it actually appears as though Eli Lilly & Bristol Myer did a trade behind the scenes as both companies acquired the companies each other were partnered with; Eli acquired ImClone in 2008 (partnered with Bristol in 2002) and Bristol acquiring Amylin in 2012 (partnered with Eli in 2002). Still the evidence suggests Eli always intended to see Amylin acquired. The whole Icahn ordeal appearing to be a big show for those not in the know.


In 1996 Amylin had an operating deficit of $155m. Like Sintx, Amylin ran into issues/experienced setbacks in R&D. Like Sintx, Amylin lost all revenue during its R&D phase but that is because J&J pulled out of the partnership while Sintx sold off its old assets to become Sintx. Just like Amylin, Sintx stock has tanked. Difference being that Amylin stock began recovering before a new collaboration was formed and obviously went up from there.

The parallels do not stop there however and just so happen to go back to the beginning of the companies.

Amylin was co-founded by Mr. Howard Greene in 1987, who just so happened to sell a company to Eli Lilly in 1986.
Sintx was co-founded by Dr Aaron Hofmann in 1996 who was a surgeon designer for Centerpulse.
Dr. Max Link was Chairman & CEO of Centerpulse from March 2002 to October 2003 when it was sold to Zimmer Holdings, Inc. That same month Dr Link became Chairman of Sintx's board.

In 1994, two former Eli Lilly executives joined the board of Amylin, the same year it went public.
2012, Dr Sonny Bal a surgeon designer for Zimmer Holdings, Inc and joined Sintx board of directors while it was still a private entity.

In 1998, one of those two former Eli Lilly executives became Chairman and CEO of Amylin.
August 2014, after Dr Link stepped down for health reasons and after Sintx went public as Amedica, February 2014, Dr Sonny Bal stepped into the role as Chairman. Then in October, Dr Bal took over as CEO as well.

It is interesting that both Amylin and Sintx were founded with ties to companies that maintained a watchful eye on development throughout their journey. For Amylin, Eli Lilly was there from the founding until 2011.

Both Joseph Cook and Dr. Bal steered their respective companies through some challenges. However by the looks of it Cook did more to put thing in order in a relative short time. Cook cut costs, just like Dr Bal and he forged ahead with development for 4 years before hitting a breakthrough. In that same time Dr Bal rebranded Amedica as Sintx, sold off old IP, and diversified Sintx direction. However, because Mr. Cook signed a development deal in 2002 with his former company Eli Lilly, Amylin had risen from the dead. This is something i still wait for Dr. Bal to do, sign some sort of agreement with the company he was a surgeon designer and scientist for since 2002. While Dr. Bal has used Zimmer Biomet IP in developing Sintx products and Zimmer Biomet hired a coatings expert in 2018, neither company has officially announced any sort of collaboration. Still you can see the similarities in both Amylin and Sintx.

Mr. Cook stepped down from his role as CEO in 2003 allowing another former Eli Lilly executive to takeover but he retained his role as Chairman until 2009. If you do the research, it was suggested that Eli Lilly intended to acquire Amylin at some point and that Amylin management was not in a hurry to sell because they could secure more money for investors, including themselves, if they waited. However it was in 2008 i believe, that Mr Carl Icahn stepped into the picture and dismantled everything. He removed Cook in 2009. Tried to get Eli Lilly to acquire Amylin, but as it turns out, Eli Lillly may not have needed Amylin like it once did. It seems it put focus on other drugs. Icahn eventually sold Amylin to Bristol Myers in 2012.

ImClone in hand and a potential approval of blockbuster prasugrel coming, Lilly needs Amylin much less than it used to.
2002 Bristol Myer signs a collab with ImClone but runs into problems. 2008, Bristol puts in an offer for ImClone but Eli acquired it with a higher offer with Icahn owning shares in ImClone. Then after selling ImClone to Eli, Icahn takes Amylin from Eli and sells it to Bristol. Looks like some backroom deal was made and the companies traded drugs somehow.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️ 1 💥 1
Atlanta1 Atlanta1 1 day ago
you are a freaking lunatic. some cretin posts hallucinogenic messages on ST and you feel compelled to do your blathering ad nauseum thing?

ya can't make this shit up, people..

theater of the absurd, starring New England's finest
👎️ 1 💩 1 🤡 1 🤮 1
boston745 boston745 1 day ago
Either the author is Asian and english is not their first language or they purposefully switched them around for possible legal reasons when propagating false information. Regardless it looks like misinformation to confuse those that might read about Zimmer Biomet and Sintx. As i said in my last post not only did this person claim Zimmer intention to acquire Sintx back in 2011, but they laid out solid reasons why they would do that through how they intended to use the tech. Primarily through licensing revenue but also to bolster their arthroplasty product lines. In addition to that it was on a forum for those that work in the ortho business so the information fits for that audience.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

Sintx 2016 10k & Feb 2017 Press Release

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

March 2021 Conference Call transcript
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️ 1 💥 1
joev2 joev2 2 days ago
He's actually calling it Lilly Eli....meant to cause confusion (or absurdity) which it obviously has. Oh, and they're paying "$5 billions dollars". Grammar at its best.....
👍️ 1
boston745 boston745 2 days ago
Over on ST someone is posting a claim (posted on some other site) that Eli Lilly is going to buy Sintx for $5 billion. There is nothing to substantiate this claim and i wonder if this is being pushed to counter a post from 2011, which you can actually verify, stating that Zimmer intended to acquire Amedica (Now Sintx) for its technology. This claim about Eli Lilly buyout could be purposeful misinformation to try to discredit Sintx ties to Zimmer which i detail in various posts below. The same funds manipulating the stock would be the most likely source of this misinformation. Something to remember/know, is when Sintx IPO'd, all references to personnel with connections to Zimmer was removed or not disclosed. Specifically the current CEO and former Chairman connections to Zimmer.
Its interesting but TAman87 called it a lie that needs to be investigated by the SEC but he doesnt say that about this following quote about Zimmer wanting to acquire Amedica (Sintx). Also this same account that is posting this supposed buyout is claiming that Sintx is changing its ISIN for M&A purposes but in fact its changing its ISIN because of the RS.


AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Unlike the Eli Lilly post, this statement can be verified and it actually provides a solid reason for why Zimmer would acquire Amedica (now Sintx). As Sintx IP has vastly expanded over the years from when this statement was made, i'd say that Zimmer Biomet would acquire Sintx to license its tech as well as use Si3N4 for arthroplasty products.

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Seems like webarchive is having some issues. You can use the core link instead to verify as its still up: https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

In regards to ISIN changes this can be caused by Reverse Splits:
https://www.isin.org/education/

This is the account i believe is propagating false information: https://stocktwits.com/joey63933

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
👍️ 1 💥 1
joev2 joev2 2 days ago
As we anxiously await for tomorrow's opening bell, I couldn't help but notice the close at .07 was 1/26 of the yearly high of 1.82. This is what Sint can and has done repeatedly over the years I.e. lose much value yoy. Yet, some wonder how this can be since management can't be blamed and products or potential products are worth supposedly hundreds of millions. Meanwhile, same management and potential partners, associates, accredited lenders simply leave the company alone as far as investing via buying stock or giving a loan through 'normal' channels. Sumthin' ain't right.

It's easy to blame unseen forces, but it makes more sense to blame those who COULD make a difference but don't. Let's begin with Sint's management team......Actually, we could end with it as well. This is why NO ONE invests (even Sint's own people) or lends (other than a Maxim type).
👍️0
boston745 boston745 2 days ago
Youd have to ask the funds manipulating the stock what they'll do with the stock.

Regardless of the stockprice the companies IP is still worth over 230m. Someday the stock may reflect the companies value.
👍️ 1 ❤️ 1
allenc allenc 2 days ago
I did not sell my shares prior to this upcoming split and more than likely a terrible move on my part. What will the share price be at Tuesday morning market open? I am hoping I can break close to even or bail at a small loss here. TIA
👍️0
Atlanta1 Atlanta1 2 days ago
olo - what a pathetic, obsessed human being.......
👎️ 1 💩 1 🤡 1
boston745 boston745 2 days ago
In a previous post i said that if Sintx was properly valued there would not be as many offerings, shares issued per offering, or reverse splits. To show just how much first, look at the previous post which breaks down the various industries and products Sintx materials can be used for. Then research a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach as it can be used for industrial, energy, aerospace, defense, anti-pathogenic, other medical products, & even cancer treatment. Consider how much those markets are all worth. Implex couldnt touch all that but it does provide a baseline valuation for Sintx IP as it was a materials company as well.

Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.

The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
The markets referenced here in Zimmers 10k are just a couple of markets Sintx Si3n4 can be used in.

Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.

Quote Sources:
https://www.sec.gov/Archives/edgar/data/1136869/000095013704001881/c83286e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013706002478/c02799e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013707002904/c12593e10vk.htm

Yes, yes, yes. Yes, thanks to Gavin,
EndFrame, a middle-out
compression platform,
is objectively worth $250 million.
Laurie couldn't vote for the platform
because she couldn't assign
a dollar value to it.
Well, Gavin has just done that.
He's validated the market,


Thus using this same logic, as Sintx is a materials company for ortho industry as Implex was, Zimmer set Sintx value for its ortho products at $232m back in 2003; Sintx tried to IPO with a valution of $225m in 2007. With inflation in market size over the last 20 years its ortho potential is worth even more. Thats not even factoring in armor, aerospace, energy, anti-pathogenic, & other potential medtech products.

========================================

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
👍️ 1
joev2 joev2 3 days ago
Sounded good, didn't it? Lol, just trying to bring some excitement to this exciting stock and company that for whatever reason, I ain't seeing. The real point I was trying to make is that IF you have the goods, the investments and alliances come. ANY company can be a forever-developing-something one....that never quite gets out there. Introducing Sint.....
👍️0
boston745 boston745 3 days ago
Hey TA, its right there in the most recent presentation. As far as what sort of role it could play in cancer treatments i do not know? However, ultrathin membranes definitely seems like a product they could be involved with. I leave the making things up to you bashers and the meme crowd.


https://i.imgur.com/FhLd8in.jpeg


Ultrathin silicon nitride membrane with slit-shaped pores for high-performance separation of circulating tumor cells

The silicon nitride (Si3N4) filtering membrane was fabricated via the standard microfabrication technology, which can be easily scaled up to mass-production. 6 µm was determined as the optimum width of the filtering pores to better separate CTCs in whole blood, which can reach a high capture efficiency of ~96%.

Image and Quote Sources:

https://d1io3yog0oux5.cloudfront.net/_8f0fdfcc546b780f57d6517861862db9/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://pubmed.ncbi.nlm.nih.gov/35997043/

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️0
Atlanta1 Atlanta1 3 days ago
wasted breath man. he can't sell 20 milion shares at 7.

he can't sell 20 million shares at 1.

are you just spoofing/tripping?
👍️0
boston745 boston745 3 days ago
In a previous post i said that if Sintx was properly valued there would not be as many offerings, shares issued per offering, or reverse splits. To show just how much first, look at the previous post which breaks down the various industries and products Sintx materials can be used for. Then research a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach as it can be used for industrial, energy, aerospace, defense, anti-pathogenic, other medical products, & even cancer treatment. Consider how much those markets are all worth. Implex couldnt touch all that but it does provide a baseline valuation for Sintx IP as it was a materials company as well.

Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.

The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
The markets referenced here in Zimmers 10k are just a couple of markets Sintx Si3n4 can be used in.

Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.

Quote Sources:
https://www.sec.gov/Archives/edgar/data/1136869/000095013704001881/c83286e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013706002478/c02799e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013707002904/c12593e10vk.htm

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
👍️0
joev2 joev2 3 days ago
What's to stop Sonny from doing the following? On Tues begin going for another one of his fundraisers at half the price. So maybe he can sell 20 million shares at 7. Voila! he has 140 million in cash and still over 229 mil shares he can authorize (and then do the same week after week until the stock is under a buck, at which time he can simply reverse split again). What can go wrong? Go Sonny! You might even be able to hire another CEO with some of that cash; get another furnace without having to wait and maybe even splurge for an all out pr campaign on what your company has to offer. I'm sure the O2's will be rolling in, along with government contracts etc....not to mention the all evasive funds buying full force, thus raising the share price to where it belongs. After all, I keep hearing you guys are way undervalued. Might even wake up some of the insiders. C'mon get this show on the road!
👍️0
boston745 boston745 4 days ago
A company with a material (Intellectual Property) that spans many industries is currently valued at basically nothing (tangible assets) and Si3N4 is not their only ceramic. Stockholders equity as of the last 10Q was $10m with intangible assets equating to $20k.
I missed something that no one has talked about from the companies presentation, Cancer treatment as new product for revenue. How can Si3n4 be used for cancer treatment? Is it filtering membrane to capture tumor cells? Is that the new market and product opportunity?

Ultrathin silicon nitride membrane with slit-shaped pores for high-performance separation of circulating tumor cells
The silicon nitride (Si3N4) filtering membrane was fabricated via the standard microfabrication technology, which can be easily scaled up to mass-production. 6 µm was determined as the optimum width of the filtering pores to better separate CTCs in whole blood, which can reach a high capture efficiency of ~96%.
https://pubmed.ncbi.nlm.nih.gov/35997043/

List of industries and potential products that they could and are developing products for. The sectors where i know they have products in development ive broken down further. Silicon Nitride could be in most healthcare related products with all its uses.

Armor (Body, vehicle, aerospace)
Energy (Accident tolerant fuel containment systems for nuclear reactors. Receiver tubes for concentrated solar-thermal power systems.)
Aviation and Aerospace Industry (combustor, radomes, and RF windows, engine ignighters, turbine blades, heat exchangers.) (Outside of Silicon Nitride are CMC for airplane engine components)
Hypersonic Industry (CMCs for hypersonics as well)
Electronics Industry (Biosensors & optics)
The Ideal Biomaterial (Spinal, Dental, Craniomaxillofacial, Foot Osteotomy & Fusion, Wound Care, Arthroplasty (Hip, Knee, Shouler, Ankle))
Antipathogenic (Masks, Medical Tubing, Surgical Gowns, Drapes, and Curtains, Filters, Consumer Products (High Touch Products), Public Transportation (High Touch Surfaces))
Biosensors
Rapid Prototyping
RF COMPONENTS
Welding
Automotive

Thats just the applications mentioned on their website, presentations, & SEC filings that i noticed. A few more are listed within the following scientific study:

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm


They have some big names behind the scenes like Morgan Ceramics & Zimmer Biomet. Im guessing Solventum as well.

========================================

Update on Sintx current market cap and float before Tuesdays RS.

Market Cap: $9,588,789
Shares Float: 141,846,000
Post RS float = 709,230

https://stocktwits.com/HaltTradeAlert/message/574273137
👍️0
joev2 joev2 4 days ago
Pfizer is dirty. Is it any wonder they were promoting COVID vacs for little kids? This is what happens when you let capitalism run amuck. We're the only western country in the world (I think) where the pharmaceutical industry is for-profit. And people wonder why I haven't gone to the doctor's for at least 10 years. Thankfully, I haven't had to. I know many MANY horror stories from wrong diagnoses to wrong prescriptions...a recent being a friend having 1 kidney removed and the other half removed due to....his hbp medication. Makes you wonder.....

Oh, and Boston....I reread your msg. No, I am not posting on ST (I see the paranoia affliction is still plaguing you). I happen to read the forum nowadays...that's all. Not that it matters. I'm sure you'll adhere to your conspiracy theories regardless.
👍️ 1
XenaLives XenaLives 4 days ago
We should all be afraid when the corporations controlling "healthcare" appear to be corrupt:

MAY 21,2024
Wyden Expands Big Pharma Tax Investigation with Pfizer Inquiry
New Letter to Pfizer CEO Builds on Three-Year Committee Investigation; The U.S. Is By Far Pfizer’s Largest Market, But Pfizer Regularly Books All Taxable Income Offshore
Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., expanded his ongoing investigation into Big Pharma’s tax avoidance and profit shifting with a new letter sent on Monday to the CEO of Pfizer. An analysis by the Finance Committee of Pfizer’s SEC filings found that the company’s effective tax rate fell by 75 percent following the passage of the Trump tax law in 2017.

“While the exact methods by which Pfizer is able to pay such low tax rates are unclear, public records indicate that Pfizer books most of its earnings offshore and benefits from changes made by the Republican tax law that lowered tax rates on foreign profits of U.S. corporations … As a result of these arrangements, there is a substantial discrepancy between where Pfizer generates prescription drug sales and where Pfizer books earnings from those drug sales for tax purposes,” Senator Wyden wrote to Pfizer CEO Dr. Albert Bourla. “In 2014 and 2015 Pfizer paid effective tax rates of 25% and 22% respectively, but paid a paltry rate of just 5.4% in 2019 and 2020. Based on this analysis, the 2017 Republican tax law was likely a major contributor to Pfizer’s effective tax rate being slashed by over 75%. The American public deserves to understand how Pfizer, a multinational pharmaceutical corporation based in the U.S. with annual sales of at least $58 billion, paid a lower tax rate than a preschool teacher or a firefighter.”

Senator Wyden began his investigation of Big Pharma’s tax practices in 2021. In 2022, he released an interim report detailing how the pharmaceutical giant AbbVie used offshore subsidiaries to avoid paying billions of dollars in taxes on prescription drug sales. He released updated findings last year that included a JCT sector-wide analysis and information gathered in further investigations of four additional pharma giants: Abbott Laboratories, Amgen, Bristol Myers Squibb and Merck.

The new Pfizer letter is available below. A complete version with footnotes included is available here.

https://www.finance.senate.gov/chairmans-news/wyden-expands-big-pharma-tax-investigation-with-pfizer-inquiry
👍️0
XenaLives XenaLives 4 days ago
Man, Zimmer even lied to me when I went to their website..

They said I could opt out of tracking on the site, but then the opt out screen did not give me that option.
👍️0
XenaLives XenaLives 4 days ago
I find your posts very enlightening, thank you.

It seems that Zimmer may have some ethics issues:



https://media.ca7.uscourts.gov/cgi-bin/rssExec.pl?Submit=Display&Path=Y2022/D03-21/C:21-1224:J:St__Eve:aut:T:fnOp:N:2848980:S:0#:~:text=Specifically%2C%20IMSS%20alleges%20Zimmer%20Biomet,to%20Mexican%20govern%2D%20ment%20officials.



Biomet Hip Implants
X-Ray of a Hip Joint Inflammation
The Biomet m2a magnum hip implant included metal-on-metal designs, which led to several complications, including metallosis.
Any individual who has received the Biomet metal-on-metal hip implant and is experiencing complications might be eligible to file a Biomet hip implant lawsuit.
There were more than 2,800 cases filed over defective hip implants, while the company settled most of the cases in 2014.
As of July 2019, Zimmer Biomet still has 190 pending lawsuits in the Multidistrict Litigation (MDL) in the federal court.
Getting a hip replacement surgery can be an overwhelming experience, but once done, you would expect to enjoy a healthy and active life. It would be devastating to continue experiencing pain, discomfort, and other issues after surgery. Unfortunately, these problems are usually caused by defective hip implants.

Biomet was one of the leading medical device companies, which was later bought by Zimmer in 2014. Zimmer Biomet became the country’s second-leading manufacturer of orthopedic implants and controlled 31% of the market by 2016. Biomet hip implants helped enhance the lives of numerous patients, but some of their products didn’t meet patient expectations, resulting in several lawsuits filed against the company.

Before these lawsuits, Biomet’s most popular products included the modular hip stem, g7 hip replacement, and Regenerex RingLoc+ Modular Acetabular System. However, the Biomet m2a magnum hip implant included metal-on-metal designs, which led to several complications, including metallosis.

Hundreds of complications were reported by patients and doctors who used the m2a magnum hip implant, but the devices were not recalled. Thousands of lawsuits were filed against Biomet, with the company eventually settling a vast number of these cases in 2014. However, there are still hundreds of cases pending.

If you or your loved one has undergone hip surgery using one of Biomet’s hip replacement implants and experienced complications, you may have the right to demand compensation for damages, losses, and for the suffering you endured.



https://www.fklegal.com/biomet-hip-implants.html
👍️0
XenaLives XenaLives 4 days ago
The only way this scenario makes any sense is if some big cartel or corporation controls the majority of the stock.

I can't understand why there wouldn't be a few of these products in production.

Something really stinks here... and it isn't the tech.
👍️0
boston745 boston745 4 days ago
A company with a material that spans many industries is currently valued at basically nothing and thats not their only ceramic. Stockholders equity as of the last 10Q was $10m with intangible assets equating to $20k.

Armor (Body, vehicle, aerospace)
Energy (Accident tolerant fuel containment systems for nuclear reactors. Receiver tubes for concentrated solar-thermal power systems.)
Aviation and Aerospace Industry (combustor, radomes, and RF windows, engine ignighters, turbine blades, heat exchangers.) (Outside of Silicon Nitride are CMC for airplane engine components)
Hypersonic Industry (CMCs for hypersonics as well)
Electronics Industry (Biosensors & optics)
The Ideal Biomaterial (Spinal, Dental, Craniomaxillofacial, Foot Osteotomy & Fusion, Wound Care, Arthroplasty (Hip, Knee, Shouler, Ankle))
Antipathogenic (Masks, Medical Tubing, Surgical Gowns, Drapes, and Curtains, Filters, Consumer Products (High Touch Products), Public Transportation (High Touch Surfaces))
Biosensors
Rapid Prototyping
RF COMPONENTS
Welding
Automotive

Thats just the applications mentioned on their website, presentations, & SEC filings that i noticed. The sectors where i know they have products in development ive broken down further. A few more are listed within the following scientific study:

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

They have some big names behind the scenes like Morgan Ceramics & Zimmer Biomet. Im guessing Solventum as well.

========================================

Update on Sintx current market cap and float before Tuesdays RS.

Market Cap: $9,588,789
Shares Float: 141,846,000
Post RS = 709,230

https://stocktwits.com/HaltTradeAlert/message/574273137
👍️ 1
boston745 boston745 4 days ago
No gameplan. Just my interpretation of the facts which the company can control. They cant control the stockprice, as evidence by even news of new revenue results in further decline in price and valuation. Stockprice is not a reflection of Sintx's fiscal health but instead a reflection of easy money for funds until, it seems, Sintx is ready to move from the R&D phase to commercialization phase. At whichpoint, i assume, all that value in IPR&D suddenly is reflected in the stockprice and valuation. Which it must be getting closer to with Sonny stepping down. Regardless of your personal thoughts on Sonny, he oversaw massive expansion of IP during his almost 10 years as CEO. That is FACT! That massive & diversified expansion represents alot of value not currently reflected in Sintx market valuation, also FACT! How much that IPR&D is worth is more subjective but we know its worth at least $232m based on what Zimmer paid for Implex material. However, Sintx addressable market is significantly larger than what Implex Hydrocel (Zimmer's Trabecular Metal) could be used for and its material is superior in just about every way as shown in the following scientific study.

TA&T was a great acquisition. Sintx armor less so based on what i know.

Business leaders have two basic drives: to add value to products or services and to deploy resources with a certain amount of efficiency.
This Sonny has done well, albeit slowly.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️0
joev2 joev2 5 days ago
Oh please, we've gone through this many times. You stick to your game plan and I'll stick to mine. Your financially astute company is on the verge of a 1/200 reverse approx 17 months after a 1/100 one. I never said anything about fear of success. Some companies do NOT handle success well. That is a fact. As far as Sint goes, regardless what you say, it is an unknown, since Sint has NEVER been successful, other than getting patents and throwing shareholders under the bus. It is a "going concern" because....it is a going concern! And how many years have they been around?

Yes, maybe I have said a lot without really saying anything, but what have you brought to the table that has helped enlighten shareholders over the years? You still can't see that shareholders for Sint have been used for only one purpose up to this point: to support a failed operation. As a potential shareholder, that says a lot! It's why I'm still not one.
👍️0
boston745 boston745 5 days ago
You've said alot without really saying anything. There is no indication of failure at Sintx anymore nor is there any indication they are not ready for success. Years ago it may have looked like failure was possible but thats no longer true. In regards to fear of success, i can see Sonny's been laying the foundation and is building toward something. What that something is exactly im not 100% sure. Using the OEM model, Sintx can license its IP without burdening itself in heavy investment which is why itll be much easier for them to succeed; very lean operation. These actions do not suggest fear of success. I dont see fear of success but instead waiting. Like waiting for Zimvie to sell spine and Solventum to complete its divestment from 3M. Things outside of Sintx are slowly coming together but im not entirely sure what the movements are meant for.
The only thing going on now is management has game changing products and is just sitting on them, waiting for whatever reason. Although sitting on them is not accurate description, but thats how it seems.
To be fiscally responsible means to manage financial resources well. Sintx does not take out high interest loans, it has no debt. It does not spend large amounts on excessive personnel and its facilities are minimal. Its cash burn is not bad considering the costs of R&D. Please go through their financials and show where there is alot of financial waste. You will not find it and no Sonny's salary is not waste nor overinflated.

I also disagree with you that they are handling things well fiscally as a company in r & d stage
Please Joe enlighten me on how they are not handling things well. To date your complaints have been almost entirely geared toward raising funds. I do agree its odd that Sonny will raise funds at lower stock prices instead of at more opportune times when things would be less dilutive. This could be connected to news. They tend to raise funds around positive news with little news in between.

SIntx already has a major stakeholder in Zimmer Biomet, it just does not own any shares YET. Because Zimmer Biomet and management do not really have shares, that allows this manipulation game to continue in regards to the stockprice. Theres a reason Zimmer's name was removed from Sintx IPO paperwork in 2013 but was there when the company tried to go public in 2007. That removal has played a part in why this manipulation game continues. I wonder if Zimmer wanted them to do that? Be interesting if Zimmer played a larger role in the manipulation of the stockprice.

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Oh and Joe, why do you care about memes on ST unless you have an account there?

========================================

it actually means the massive issuance of dilutive new shares can continue.....
Where was this comment last year Atlanta? Shareholder rights offerings are the best protection against dilution but it looks like youre trying to play peoples fear. I suggest holding minimal shares so one can participate in rights offerings..multiplied by 200 to account for the RS. Best way to minimize risk while staying in the game until funds are done gaming this; otherwise keep watching because the tech is very valuable. First clue they are about done is Sonny stepping down. Next will be management buying shares.

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
👍️0
joev2 joev2 5 days ago
Absolutely!
👍️0
Atlanta1 Atlanta1 5 days ago
it actually means the massive issuance of dilutive new shares can continue.....
👍️0
joev2 joev2 5 days ago
And with this, we KNOW Sint can keep the reverse splits going.
The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.
👍️0
joev2 joev2 5 days ago
One of the major reasons companies fail is because they don't know how to handle success. People often talk about failure due to lack of sales etc. However, there is a flip side. Fiscal responsibility is a different game then and is not guaranteed. As of now, no one knows whether or not Sint can even handle any sort of achievement that would normally bring major investors in. Thus my comment about "fiscal responsibility". I also disagree with you that they are handling things well fiscally as a company in r & d stage, but that's neither here nor there.

Vivek R took an activist stake in Buzzfeed recently and it caused the stock to fly. Sint never has ANYONE taking a stake and that's meaningful! As I've said numerous times before...the reason Sint is manipulated (and it is) is because it can be. Not every company makes it so easy. This I have placed and continually place, on the shoulders of management. They're not the first to have gone public without a clue, and undoubtedly won't be the last. Maxim and others look forward to doing 'business' with them and others like them. And gamers of all sorts know what to do each and every time as well. Do you have ANY idea why Sint went for a 1/200? I would guess not and I bet neither do they. Thus, my continuing negative view concerning leadership...

One thing I look forward to is the great decrease in stupid memes and posts on ST. I guess there's a silver lining here after all.
👍️0
boston745 boston745 5 days ago
Revenue is improving but its negligible compared to the companies potential with the various product candidates its sitting on; like laser sintering ZTA implants with Si3N4 to improve their performance. The company is fiscally responsible with low cash burn rate for a company in R&D phase. It has essentially no debt. Its IP is worth hundreds of millions plus, yet you're arguing that the stockprice has no support without contracts? It has no support due to manipulation and naked shorting. Even as contracts have come in its not helped the stockprice. Every bit of positive news has been shorted or naked shorted depending on when the news is released. What is problematic with Sintx is Sonny just sits on all these products without much attempt to commercialize; Atlantas criticism of Sonnys snail pace is accurate but what we dont know is why Sonny just sits on products candidates like that? Guess the new CEO will finally begin commercializing everything Sintx is currently sitting on. That IP has value even if its not generating revenue yet.
Another example of a product candidate that seems to be just sitting on the shelves is masks. There was an attempt to bring masks to market in 2021 but that failed. Why are we now in 2024 and still no new attempt to commercialize with different and better partner? Is this because we've been waiting on 3m divestiture of Solventum to complete? Thats done, now what? The 10k mentions lots of strategic partnerships and thats where things seem to stay for years on end.
Sonny did funds a favor doing with a 200:1 so they can short from 16 or whatever instead of 8 or whatever. Lets see if the price drops 50% once the next offering is announced and then drops another 50% post offering like all of 2023 offerings. What happened in 2023 into Q1 2024 wasnt the result of companies poor performance but pure manipulation which can be seen clearly on the chart; egregious manipulation of the stock actually began in 2022 when the stock began to nosedive wihtout anything inherently negative happening with the company to justify it. Hey TA what to give an updated chart?

Solventum's CEO Bryan Hanson knows all about Si3n4 from his days at Zimmer Biomet. It is curious that Mr Hanson left Zimmer Biomet for Solventum which sells the very products that Si3n4 anti-pathogenic features are perfect for.

We have several partnerships exploring opportunities in face masks, filters, wound care, and coatings.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm


https://i.imgur.com/xMRDE8n.jpeg


========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439


Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
👍️ 1
joev2 joev2 5 days ago
Hmm, if I was the CEO of Sint and my stock was trading at 10 cents or so and I had already committed to a 1/100-1/300 reverse, what would I do? I don't think I'd have a clue...probably just throw a dart or go in between (for no real reason). Unfortunately, I feel this is basically what this bod did....which is one of the reasons why the company trades the way it does. Assuming, the 1/200 goes at .08, you'll have a 16 dollar stock with nothing to really keep it there. Yes, one can say it's improving, but certainly not enough to offset expenses OR show it's worth the price. Unless or until the contracts come in and the company shows it knows how to be fiscally responsible....nada. 10q's like the last one, hardly fan the flame. However, pumpers and penny players must LOVE Sint, when it's time to drop in for a season.
👍️ 1
XenaLives XenaLives 6 days ago
He also discusses the manipulation of this stock, which is rather obvious. He does not talk about personal investment.
👍️0
Atlanta1 Atlanta1 6 days ago
lol - what does the term "haircut" have to do with discussing the science?
👍️0
XenaLives XenaLives 6 days ago
He's been discussing the science - which is valid.

I have not seen him discussing investment, which is rigged apparently.

I more than doubled my money this time, but I kept one share to watch.
👍️0
Atlanta1 Atlanta1 6 days ago
HIlarious. You've been on a permanent haircut binge for years with SINT.
👍️0
triannual triannual 6 days ago
1/200 r/s on May 28th to meet compliance.
👍️0
boston745 boston745 6 days ago
SINTX was notified by IP Australia, the country’s patent authority, of award of patent number 2020334770, Methods of surface functionalization of zirconia-toughened alumina with silicon nitride. This patent covers methods to enhance the osteogenic properties of alumina and zirconia-toughened alumina (ZTA) materials, commonly used in joint replacement applications, by directly bonding a thin layer of bioactive silicon nitride powder to the oxide’s surface using a laser. The supporting documentation provided with the patent application demonstrated more favorable bone cell response, maturation, and mineralization when oxide surfaces were laser-coated with silicon nitride powder. This technology offers manufacturers of alumina and ZTA devices a relatively inexpensive method to enhance osteogenic activity on specific surfaces of their existing inventory and designs as desired.
Nice, laser coating can be applied to existing inventory! Is there a US patent on this? This patent was dated August 19th 2019. Almost 6 years to get awarded, sheesh.

US patent: https://www.freepatentsonline.com/y2022/0289637.html


Osteogenic Enhancement of Zirconia-Toughened Alumina with Silicon Nitride and Bioglass®

Recent work has suggested the application of Al2O3 and ZTA in spine fusion and dental implants [48,49,50,51,52]. Biomaterial surface chemistry, and prior clinical experience with Al2O3-coated hip implants suggests caution, however. To combine the long-term structural reliability of ZTA with enhanced bone healing, surface functionalization with highly osteogenic materials like Bioglass®/Si3N4 may be a strategy to protect host tissues from aluminum ions, while promoting osteogenesis.

Quote Sources:
https://www.linkedin.com/posts/sintx_sintx-was-notified-by-ip-australia-the-country-activity-7199398753668120576-KkAR
https://www.mdpi.com/2571-6131/2/4/43

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️ 1
boston745 boston745 6 days ago
Ok so offering Q3. Need to see the naked short numbers. Usually the price takes a haircut post RS. Buy just enough shares to participate in any shareholder rights offerings post RS.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
👍️0
CarlCarlMcB CarlCarlMcB 6 days ago
Whale on $$$$$$ start reeling $$$$$$$
👍️ 1
MASTERULTRA MASTERULTRA 6 days ago
DEAD Money. Reverse split Game Over!
👍️0
Jaxxm Jaxxm 6 days ago
BS reverse split anoncement killed
👍️0

Your Recent History

Delayed Upgrade Clock